It remained unclear whether tyrosine kinase inhibitors (TKIs) related renal impairment had impact on the survival of patients with metastatic renal cell carcinoma (mRCC).
Clinicopathological parameters of patients with mRCC treated with TKIs were retrospectively reviewed.